# Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.

> **NCT06922903** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Yunhe Pharmaceutical (Tianjin) Co., Ltd** · enrollment: 240 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** INR101

## Key facts

- **NCT ID:** NCT06922903
- **Lead sponsor:** Yunhe Pharmaceutical (Tianjin) Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06922903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06922903, "Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06922903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*